. The Act directs NHTSA to maintain an up-to-date list of registrants and a list of the make and model of motor vehicles exempted on at least an annual basis and publish such list in the Federal Register or on a website operated by NHTSA. The FAST Act requires, at section 30114(b)(3), that NHTSA require low-volume manufacturers to affix permanent labels to the exempted motor vehicles that identify the specified

CMV. Information on motor carriers, including their most current safety rating, is available from the FMCSA Safety and Fitness Electronic Records System website at https://safer.fmcsa.dot.gov, or by telephone at (800) 832-5660.

, please visit https://www.epa.gov/​dockets/​commenting-epa-dockets. The https://www.regulations.gov/​ website allows you to submit your comment anonymously, which means the EPA will not know your identity or contact information unless you provide it in the body of your comment. If you send an email comment directly to the EPA without going through https://www.regulations.gov/​, your email address

of the rule. The amendments are environmentally neutral. DATES: This final rule is effective on February 8, 2019. ADDRESSES: The EPA has established a docket for this action under Docket ID No. EPA-HQ-OAR-2017-0358. All documents in the docket are listed on the https://www.regulations.gov website. Although

its website in the credit card agreement database.[80] In addition, the Bureau collects annually and publishes on its website college credit card marketing agreement data and credit card issuers' marketing agreements with colleges, universities, and their affiliates, as well as the number of cards covered by, and the amount of payments made by issuers under these agreements.[81] The Bureau also collects information semi-annually from certain card

CMV. Information on motor carriers, including their most current safety rating, is available from the FMCSA Safety and Fitness Electronic Records System website at https://safer.fmcsa.dot.gov, or by telephone at (800) 832-5660.

consider as part of a classification decision whether an indication or a device is covered by commercial health insurance companies. FDA recommends that patients check with their insurance company regarding coverage before receiving CES treatment. (Comment 7) One comment stated that a manufacturer's website of a currently marketed CES device includes misleading marketing material that may persuade consumers to use this device. The comment also claims that the

“Security Information” tab in EMMA® at https://emma.msrb.org when describing the tax-advantaged bond in SLGSafe. If the EMMA® website revises its naming convention, the Issuer would supply the updated registration as it is presented in EMMA®, or its successor system. The Issuer would be able to input the “EMMA® registration” into SLGSafe at the time the subscription is started (§ 344.5

confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received: http://www.regulations.gov. Follow the search instructions on that website to view public comments. CMS will not post on Regulations.gov public comments that make threats to individuals or institutions or suggest that the individual will take actions to harm the individual. CMS

INFORMATION: This is a summary of the Commission's Notice of Proposed Rulemaking (Notice) in WC Docket No. 20-71, adopted March 31, 2020 and released April 1, 2020. The full text of this document is available for public inspection during regular business hours in the FCC Reference Information Center, Portals II, 445 12th Street SW, Room CY-A257, Washington, DC 20554. It is available on the Commission's website at https

RIN 3064-AF35, by any of the following methods: Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments in the portal. Agency Website: https://www.fdic.gov/​regulations/​laws/​federal/​. Follow the instructions for submitting comments on the website.

comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received: http://www.regulations.gov. Follow the search instructions on that website to view public comments. Wage index addenda

comments on the Commission's website (https://www.sec.gov/​rules/​proposed.shtml). Comments also are available for website viewing and printing in the Commission's Public Reference Room, 100 F Street NE, Room 1580, Washington, DC 20549, on official business days between the hours of 10:00 a.m. and 3:00 p.m. All comments received will be posted without change. Persons submitting comments are cautioned that we do not redact or edit personal identifying information from comment submissions. You

ensure the proper execution of PPACA requirements and to safeguard and conserve federal funds. To protect against unnecessary overpayments of APTC funds, we will streamline the process for terminating coverage of enrollees who die while enrolled in Exchange coverage. In order to ensure that MLR reporting and rebate calculations are accurate, we are finalizing the proposal that issuers must report expenses for functions outsourced to or services provided by other entities consistently with issuers

) registration number of the company that originated the loan. (27) Buy down period. Indicate the total number of months during which any buy down is in effect, representing the accumulation of all buy down periods. (28) Loan delinquency advance days count. Indicate the number of days after which a servicer can stop advancing funds on a delinquent loan. (29) Information related to ARMs. If the loan is an ARM, provide the following additional information: (i) Original ARM Index

FC friction compensation error horsepower or watt W m2·kg·s−3.

, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received: http://www.regulations.gov. Follow the search instructions on that website to view public comments. Table of Contents To assist readers in

, 2019, with EPA's posting of the availability of the submittal on EPA's Adequacy website (at https://www.epa.gov/​state-and-local-transportation/​state-implementation-plans-sip-submissions-currently-under-epa). The comment period ended on June 1, 2019. EPA did not receive any requests for this submittal, or adverse comments on this adequacy submittal. In a letter dated June 5, 2019, EPA informed Ohio EPA that we found the 2023 and 2030 MVEBs to be adequate for use in transportation

1 the Secretary shall approve and make available in print and on the Administration's internet website a 5-year roadmap for the introduction of civil unmanned aircraft systems into the national airspace system, as coordinated by the Unmanned Aircraft Program Office of the Administration. The Secretary shall update, in coordination with the Administrator of the National Aeronautics and Space Administration (NASA) and relevant stakeholders, including those in industry and academia

identification UAS. Persons would be able to meet this obligation by ensuring that the serial number of the standard remote identification UAS is listed on an FAA-accepted declaration of compliance. A person operating a UAS would be able to read the label on the aircraft indicating whether the UAS is a standard or limited remote identification UAS. Additionally, a person could determine whether the UAS is listed on an FAA-accepted declaration of compliance by verifying the status on the FAA's website. The

section 344 or 379e of this title. (2) Making, selling, disposing of, or keeping in possession, control, or custody, or concealing any punch, die, plate, stone, or other thing designed to print, imprint, or reproduce the trademark, trade name, or other identifying mark, imprint, or device of another or any likeness of any of the foregoing upon any drug or container or labeling thereof so as to render such drug a counterfeit drug.